<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462397</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000540233</org_study_id>
    <secondary_id>UCLCTC-BRD/05/22-CERVIX</secondary_id>
    <secondary_id>EUDRACT-2005-000134-20</secondary_id>
    <secondary_id>CRUK-BRD/05/22</secondary_id>
    <secondary_id>EU-20720</secondary_id>
    <secondary_id>UCLCTC-CERVIX</secondary_id>
    <nct_id>NCT00462397</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer</brief_title>
  <official_title>Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Giving combination chemotherapy together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin&#xD;
      followed by cisplatin and radiation therapy works in treating patients with stage IB, stage&#xD;
      II, stage III, or stage IVA cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate, in terms of clinical or radiologic response at 12 weeks&#xD;
           after completion of study therapy, in patients with stage IB2-IVA cervical cancer&#xD;
           treated with neoadjuvant chemotherapy comprising dose-dense paclitaxel and carboplatin&#xD;
           followed by radical chemoradiotherapy comprising concurrent cisplatin and radiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate in patients treated with this neoadjuvant chemotherapy&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the toxicity of this neoadjuvant chemotherapy regimen in these patients.&#xD;
&#xD;
        -  Assess the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Neoadjuvant chemotherapy: Patients receive neoadjuvant chemotherapy comprising&#xD;
           paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats&#xD;
           weekly for up to 6 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning in week 7, or as soon as blood counts recover, patients&#xD;
           receive cisplatin IV over 1 hour on day 1. Treatment repeats weekly for 4-6 courses in&#xD;
           the absence of disease progression or unacceptable toxicity. Patients also undergo&#xD;
           concurrent radiotherapy comprising pelvic external beam radiotherapy once daily for 5½&#xD;
           weeks (5 weeks for patients with positive para-aortic lymph nodes) and 2 applications of&#xD;
           high-dose rate intracavitary brachytherapy or low- or medium-dose rate brachytherapy.&#xD;
           Patients with parametrial or pelvic sidewall disease extension also undergo external&#xD;
           boost radiotherapy for 3 days.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at the end of chemoradiotherapy (i.e., 12 weeks after completion of study therapy)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate at the end of neoadjuvant treatment (i.e., 6 weeks after study entry)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the cervix, including any of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Adenosquamous cell carcinoma&#xD;
&#xD;
          -  Locally advanced disease (i.e., FIGO stage IB2-IVA disease)&#xD;
&#xD;
               -  Stage confirmed by examination under anesthesia, cystoscopy, and sigmoidoscopy&#xD;
                  with biopsy of any suspicious lesions in the bladder, vagina, or rectum&#xD;
&#xD;
          -  Disease suitable for treatment with radical intent using chemoradiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 12.5 g/dL&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) normal by ethylenediaminetetraacetic acid (EDTA) OR&#xD;
             creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Placement of ureteric stents required for all patients with hydronephrosis, regardless&#xD;
             of renal function&#xD;
&#xD;
          -  ALT or AST &lt; 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No prior diagnosis of cancer, except basal cell skin cancer&#xD;
&#xD;
          -  No active cardiac disease&#xD;
&#xD;
          -  Deemed fit to receive chemoradiotherapy&#xD;
&#xD;
          -  ECG normal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary McCormack, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Paul Symonds, MD, FRCP, FRCR</last_name>
      <phone>44-116-258-6296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter R. Blake, MD</last_name>
      <phone>44-20-7808-2581</phone>
      <email>peter.blake@rmh.nthames.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary McCormack, MD</last_name>
      <phone>44-20-7380-9302</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

